PERFUSE: A French Prospective/Retrospective Non-interventional Cohort Study of Infliximab-naive and Transitioned Patients Receiving Infliximab Biosimilar SB2; 1st Interim Analysis

(1) Beaujon Hospital, AP-HP, Paris Diderot University,Clichy,France

(2) AP-HP, Pitié-Salpêtrière Hospital,Paris,France

(3) E-health Services Sanoïa, Digital CRO,Gémenos,France

(4) Biogen Idec Ltd,Maidenhead,United Kingdom

(5) Biogen France SAS,Paris,France

This item was part of the IBD II (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019